Home
Injectable Drug Delivery
8 May - 9 May 2024
Injectable Drug Delivery

Injectable Drug Delivery is an industry focused on two overarching topics the development of the device & the interaction between drug product and device. SAE’s 2024 Injectable Drug Delivery conference brings together a complete big pharma speaker line-up providing technical updates on the relationship between drug product formulation and the device primary packaging, with considerations for formulation strategies, extractables & leachables and toxicological testing of injectable devices.


This conference brings case studies from senior big pharma representatives providing an opportunity to discuss formulation considerations in depth for parenteral packaging, this is the perfect opportunity to benchmark your drug delivery programme and optimise the development of your injectable portfolio.
 

FEATURED SPEAKERS

Julian Dixon

Julian Dixon

Senior Director, AstraZeneca
Ryan Noble

Ryan Noble

Associate Director, Devices, GSK
Selenge Erdenechimeg

Selenge Erdenechimeg

Global Regulatory Specialist | RA Device Combination Products, Novo Nordisk
Simon Wilson

Simon Wilson

Device Development Lead, Pfizer
Soumen Das

Soumen Das

Associate Scientific Fellow, Takeda

Alfredo Ricci

General Manager, Platinum Pharma Service srls
Alfredo Ricci

Berna Kosekaya

Regulatory Professional, Novo Nordisk
Berna Kosekaya

Berna Kosekaya is an expert in regulatory affairs at Novo Nordisk, where she is responsible for driving global submissions for the combination products portfolio within a dynamic regulatory landscape. With a robust background as a pharmacist holding a Ph.D. in pharmacology, she brings a wealth of knowledge and expertise to her role. Her career journey includes pivotal roles within the national medicines agency of Turkiye. With over 8 years of regulatory experience spanning diverse product portfolios, her current focus is on navigating the complexities of combination products with precision and efficiency.

Cedric Gysel

Manager, Sustainable Innovation & Circular Economy Solutions at the Office of Sustainability , Johnson & Johnson
Cedric Gysel

Cedric Gysel is a Healthcare Solutions Manager for Johnson & Johnson Design, driving human-centered solutions for patients and customers and leading key innovation projects for device & packaging sustainability as we all product end of life programs across the pharmaceutical and medical device sectors of Johnson & Johnson. He has more than 15 years of experience with the development and design of devices and combination products. He holds a bachelor’s in pharmaceutical technology from the University of Basel and a master’s in medical device technology from the University of Applied Science.

Christian Proff

Senior Verification Engineer, Roche
Christian Proff

Dr. Christian Proff is a materials scientist with degrees from Chalmers, Gothenburg (S) and Darmstadt (D) Universities of Technology and a PhD from Grenoble (F) University (INPG) with extensive experience in materials research in Sweden (Chalmers), USA (Argonne National Laboratory) and Switzerland (Paul-Scherrer-Institut). Within Device and Packaging Development at F. Hoffmann - La Roche he is working in Verification Engineering since 2018 on improvements in CCI testing and development of new device test methods.

Cinzia Rotella

Project Leader, Sanofi
Cinzia Rotella

Cinzia holds a degree in Materials Science and a PhD in Polymer physics from the KULeuven University. She has joined Sanofi in 2016 as a Sr. Materials Scientist and she is now Project Leader for Life Cycle Management activities in the Medical Device Unit

Clemens Gunther

Director, Senior Expert Nonclinical Safety, Bayer AG
Clemens Gunther

Estefania Dos Anjos

Senior Product Specialist, TÜV SÜD
Estefania Dos Anjos

Fatima Bennai-Sanfourche

Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG
Fatima Bennai-Sanfourche

Dr. Fatima Bennai-Sanfourche is working currently as Senior Director of QA&RA Compliance for Medical Devices, Combinations Products, and eHealth at Bayer AG.
Previously she worked in the medical affairs and Pharmacovigilance department at Bayer as Director, Medical Device Safety Global Pharmacovigilance/Medical device Safety officer.
She has more than 15 years of experience in the quality management and Regulatory Affairs of medical devices field, and over 20 years of supervisory and leadership experience including hiring, training and performance evaluation.
She studied Biology with a focus on Biochemistry, Immunology and Pharmacology, and did her PhD in Pharmacology and Pharmacochemistry in Strasbourg in France. She started her professional life with more university-oriented areas doing research and development in France, Sweden and Germany with a focus on cerebrovascular diseases, such as stroke, regulation of hypertension and development of immunoassays.
In her current position by Bayer AG her focus is ensuring the regulatory compliance as well as high product quality of medical device, combination products and eHealth components of the Pharmaceuticals portfolio.
She is also responsible for Ensuring compliant use of medical devices and medical software tools in the context of clinical investigations and clinical trials, incl. accordance with medical device Good Clinical Practice (GCP).
She is also leading the project of the implementation of euMDR for PH-Bayer AG.
She was nominated in 2019 by the European Commission as EFPIA observer for the PMSV (Post-Market Surveillance and Vigilance) subgroup (GROW.D4) responsible for the implementation of these process according the medical Device regulation. The period of nomination is of five years starting on 01 March 2019.

George Moore-Arthur

Senior Global Regulatory Professional, Novo Nordisk
George Moore-Arthur

Following an BSc in Biomedical science and MSc in Biotechnology I am currently working at Novo Nordisk as a global regulatory professional responsible for driving regulatory strategy in key global markets for Novo Nordisk digital health & IVD products. Prior to joining Novo Nordisk, I worked for the UK regulatory agency (MHRA) in various roles including medicinal pharmaceutical products and safety & surveillance for a range of medical devices (including surgical, wound management and IVD devices).

Hiroki Hasegawa

Assistant Research Manager, Mitsubishi Gas Chemical Company, Inc
Hiroki  Hasegawa

Mr. Hiroki Hasegawa is a researcher of Advanced Business Development Division.
He gained a Diploma in Science in 2013 and a Master Degree of Science in 2015 from Osaka University.
Since April 2015 he has been working for Mitsubishi Gas Chemical Company, Inc. and in charge of macromolecular science,
especially in composition development of thermosetting resin.
Since 2018 he has joined a development team of multilayer plastic vial & syringe for biologics.

Julian Dixon

Senior Director, AstraZeneca
Julian Dixon

After 24 years at Team Consulting supporting the development of drug delivery devices, Julian joined AstraZeneca biopharmaceutical development in 2022 to be in one of the key player organizations as the future of combination product human factors is being shaped. Julian’s background is in mechanical engineering and psychology. Both have remained fascinating and provide more than enough fuel for continued curiosity.

Marc Egen

Head of Primary Packaging & Process Development, Boehringer Ingelheim Pharma Gmbh & Co. KG
Marc Egen

Marc is a polymer chemist by training and joined Boehringer Ingelheim more than 20 years ago. He was working in various positions at the interface between Development and Operations. Dealing mostly with pharmaceutical technology, manufacturing, and packaging processes, he gained experience in inhalation drug product development, solids manufacturing, launches and transfers, and solids and parenteral packaging development.

Morgan Amsler

Director of Business Development, ApiJect Systems, Corp.
Morgan Amsler

Morgan Amsler has over 12 years of experience leading mid-market life science and medical device business growth initiatives including sales, corporate strategy, and new business development. At ApiJect, Mr. Amsler leads business development efforts to manage licensing agreements with companies developing injectable combination products using the ApiJect technology platform. Prior to his current position, Mr. Amsler served for 10 years in progressively responsible roles at Halma, plc, a FTSE100 listed holding company with over 50 subsidiaries focused on health and safety. Most recently at Halma, Mr. Amsler lead a subsidiary, Arcmed, as Vice President of Sales & Business Development and an Executive Board Member where he managed organic and acquired growth initiatives and strategy through the integration and transformation of two leading life science manufacturers. His previous positions in Halma's Healthcare Sector include Director of Innovation, New Product Development Manager, and a Founding member of the Future Leaders Program. Mr. Amsler earned his MBA from Columbia Business School and a Bachelor's Degree with a focus on Biomedical Engineering from Vanderbilt University. He also volunteers with the United States National Inventor’s Hall of Fame as a Judge at the annual Collegiate Inventors Competition.

Ryan Noble

Associate Director, Devices, GSK
Ryan Noble

Ryan Noble is an Associate Director at GSK in the Global Regulatory Affairs Devices Team. He is currently focused on integrating device engineering and drug product development to ensure regulatory compliance with the ever-changing regulatory landscape. Ryan has been working in combination product development for 25 years and has experience in testing, formulation, manufacturing, quality systems, and regulatory processes throughout the lifecycle of both respiratory and parenteral systems.

Selenge Erdenechimeg

Global Regulatory Specialist | RA Device Combination Products, Novo Nordisk
Selenge Erdenechimeg

Selenge is a Combination Products Regulatory Specialist for Devices at Novo Nordisk and is responsible for driving fast paced regulatory submissions in the growing combination products market in US with the FDA, in EU with EMA and Notified Bodies. She brings more than 10 years of experience to Novo Nordisk.
As a former Global Regulatory Strategist in Pfizer Devices Centre of Excellence Cambridge UK and a TOPRA member, she has worked with combination products regulations and design control compliance.
Selenge holds Postgraduate degree in Regulatory Affairs in Medical Devices from TOPRA and has undertaken BSc in Biochemistry from Monash University, Australia.
 

Simon Wilson

Device Development Lead, Pfizer
Simon Wilson

Simon has spent over 30 years developing a wide range of products since graduating with a degree in Engineering Product Design. These have included consumer goods, handheld computers and mobile communications devices as well as a stint at a major London design consultancy. He joined Pfizer’s Cambridge based Device Centre of Excellence, DCoE, in 2007.
Whilst working for Pfizer, Simon has managed parenteral device development projects through from initial concept to clinical trials and beyond. Simon has worked on several digitally ‘connected’ device projects, helping to liaise between teams developing devices and mobile apps or other digital elements.
 

Soumen Das

Associate Scientific Fellow, Takeda
Soumen Das

Soumen Das is an experienced professional in the field of product development within the medical device industry, with a track record spanning over nine years. For the past five years, Soumen has dedicated his efforts to ensuring the biocompatibility of medical devices for the FDA, EU, and PMDA regulatory submissions. His expertise ranges from in-vitro diagnostics to implantable medical devices. His Ph.D. and postdoctoral work focused on material and nanoparticle compatibility with biology, including systemic and organ toxicity. His extensive research has resulted in over fifty peer-reviewed international journal publications showcasing his commitment to advancing the field. He holds eight patents alongside his publications, demonstrating his innovative and creative problem-solving abilities. Recognized for his achievements, Soumen has been honored with several prestigious awards, including the Young Investigator Award 2016 and the 2014 at Gordon Conference in Radiation Chemistry. Additionally, he received the University of Central Florida Innovator Award in 2014.

Victoria Ludlow

Program Manager, MediPhorum
Victoria Ludlow

BioPhorum is a collaboration of industry leaders and subject matter experts working together to pool knowledge, best practice, and ideas – these outputs lead to results that effect real progress.
Our mission is to create an environment where our members from the global biopharmaceutical and device industries connect, collaborate and accelerate progress – for the benefit of all.

What will you gain?

  • Evaluate how devices can be co-developed alongside drug products to foster a collaborative approach to improve biocompatibility and effective toxicological testing
  • Expand on design strategies for injectable delivery of advanced modalities, including cell and gene therapies, large molecule delivery and sub-zero device requirements
  • Learn through focused presentations tailored to a technical device development and primary packaging audience, exploring vial material and primary component selection, silicone layer thickness studies and standardisation of primary container formats
  • Benefit from spotlight sessions focusing on sustainable device materials, offering comprehensive perspectives on material development and selection through to disposal
  • Learn how major device developers are streamlining product development and CMC practices for effective compliance throughout and post-NDA/MAA approval

 Who should attend?

Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:

  • Autoinjectors
  • Wearables
  • Device Engineering
  • Human Factors
  • CMC
  • Injectables
  • Sterile Manufacturing
  • Packaging
  • Regulatory Affairs

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chair's Opening Remarks

Fatima Bennai-Sanfourche, Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG

clock

9:10

What should combination product human factors engineering (CP HFE) look like in 2034?

Julian Dixon, Senior Director, AstraZeneca

  • Are we still on a learning curve or have we reached a knowledge plateau?
  • Our business is one of platforms. How will the reuse of existing drug delivery platforms – and the creation of new ones - be reflected in CP HFE?
  • In what ways will we be more truly patient-centric?
  • clock

    9:50

    Empirical and digital tools for plunger stoppers characterization

    Cinzia Rotella, Project Leader, Sanofi

  • The presentation describes the approach used to characterize and discriminate different plunger stoppers
  • The characterization was performed by using empirical tests – standards & ad-hoc methods – and model digital twins
  • The approach was used to build a guideline for stopper selection inside Sanofi
  • clock

    10:30

    A customer-centric approach to the medical device development: a full turnkey service

    Alfredo Ricci

    Alfredo Ricci, General Manager, Platinum Pharma Service srls

  • Why it is so important to have a customer centric approach in order to develop a new medical device
  • Which advantage in having a full turnkey service 
  • Two cases study: why being fast and flexible add value to the customer
  • clock

    11:00

    Morning Break

    clock

    11:30

    Evaluaton of Extractables and Leachables for Pre-filled Syringes

    Clemens Gunther

    Clemens Gunther, Director, Senior Expert Nonclinical Safety, Bayer AG

  • Introduction: why do we need to care about E&L?
  • How to perform an E & L investigation? 
  • Principles of a Toxicological Risk Assessment on E & L
  • clock

    12:10

    Change management and CMC best practices for streamlined injectable device development

    Ryan Noble, Associate Director, Devices, GSK

  • The latest updates in European regulatory guidance and MDR 
  • CMC guidance in approaching the injectable combination product development and change management lifecycle
  • Assessing interpretations across device and pharma landscapes, how can we control for differences across health authorities, notified bodies and industry
  • Projections and opportunities for improved alignment in change management across drug-device development teams
  • clock

    12:50

    Networking Lunch

    clock

    13:50

    FDA's Platform Technology Designation Program

    Selenge Erdenechimeg, Global Regulatory Specialist | RA Device Combination Products, Novo Nordisk

  • Are device delivery platforms in scope of this new program
  • The why(s) and the how(s)
  • Future opportunities and way forward
  • clock

    14:30

    Session Reserved for Apiject

    Morgan Amsler, Director of Business Development, ApiJect Systems, Corp.

    clock

    15:00

    Afternoon Break

    clock

    15:30

    Container Closure Integrity of OXYCAPT Vial at Deep Cold Storage

    Hiroki Hasegawa, Assistant Research Manager, Mitsubishi Gas Chemical Company, Inc

  • Overview of OXYCAPT Vial
  • Oxygen & Carbon Dioxide Barrier
  • Break Resistance at -80 & -180?
  • CCIT at -80?
  • Comparison of CCIT among OXYCAPT, Glass and COP
  • clock

    16:00

    MediPhorum: Presenting a working tool for Device Design Changes [form, fit, function] to Drug Delivery Devices Post-Launch

    Victoria Ludlow, Program Manager, MediPhorum

  • An interactive document to support technical engineers in parallel to regulatory teams
  • MediPhorum Membership has developed a US based 'decision tree' tool which combines several guidance / frameworks and provides further user-guidance and case-studies across seven categories of design change, including key lists of considerations/evaluation for assessing if a design change is needed, and provides a library of justifications / evidence supporting why / why not
  • clock

    16:30

    Chair’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chair's Opening Remarks

    Fatima Bennai-Sanfourche, Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG

    clock

    9:10

    Notified Bodies’ Perspectives: Injectable Device Development

    Estefania Dos Anjos

    Estefania Dos Anjos, Senior Product Specialist, TÜV SÜD

  • Outlining key primary packaging requirements
  • What is needed for a successful submission and NB opinion?
  • How industry can work more closely with regulators and notified bodies in implementation of new regulations
  • Challenges in lifecycle management of combination products
  • clock

    9:50

    CCI compliance challenges after (recent) regulatory updates

    Christian Proff, Senior Verification Engineer, Roche

  • USP<1207> and EU Annex 1
  • Expectations for pharmaceutical packaging development and lifecycle management
  • Details available from thorough packaging development which supports compliance to regulatory requirements
  • Typical examples we will shed light on selected aspects of individual packaging solutions

     

  • clock

    10:30

    Notified Body Opinion Considerations for Post-Authorization Changes

    Berna Kosekaya, Regulatory Professional, Novo Nordisk

  • What constitutes a non-substantial change?
  • What is the threshold for requiring an updated Notified Body Opinion?
  • What are the main challenges?
  • clock

    11:00

    Morning Break

    clock

    11:40

    Primary Packaging Supplier Selection and Portfolio Management

  • Selection Panel, fit for purpose
  • Deep dive into some important materials properties
  • Packaging portfolio management
  • Marc Egen, Head of Primary Packaging & Process Development, Boehringer Ingelheim Pharma Gmbh & Co. KG

    clock

    12:20

    Risk Management Process for Connected Drug-Devices Combination product

    Fatima Bennai-Sanfourche, Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG

  • Introduction : The future of patient care.
  • Impact of the EU MDR on connected drug-device risk management process
  • Cybersecurity
  • Usability engineering/Human Factors (HF)
  • Benefit-risk assessment of connected drug-device combination product
  • clock

    13:00

    Networking Lunch

    clock

    14:00

    Selection of a new primary component: an interdisciplinary approach

    Soumen Das, Associate Scientific Fellow, Takeda

  • Understanding the importance of primary packing from the perspective of drug development
  • Optimising the process development approach can reduce lead times into manufacturing
  • Standardisation of primary container formats
  • Engagement of manufacturing and device development functions
  • clock

    14:40

    Ensuring Patient Safety through Interoperability and Cybersecurity in Connected Drug Delivery Solutions

    George Moore-Arthur, Senior Global Regulatory Professional, Novo Nordisk

  • Interoperable devices and changing landscapes
  • Cybersecurity risks and threats
  • Regulatory requirements for cybersecurity in medical devices

     

  • clock

    15:20

    Afternoon Break

    clock

    15:50

    Strategies to manage partner relations for collaborative, user-centric development teams

    Simon Wilson, Device Development Lead, Pfizer

  • Challenging the old school supplier-customer relationship: why complex projects require dynamic collaboration
  • Managing effective relationship building with suppliers as well as supplier sub-contractors to advance innovation
  • Working frameworks for improved synergy to ensure streamlined development of optimal user-centric devices
  • Looking forward: Toolkit for effective external stakeholder management for parenteral devices of the future

     

  • clock

    16:30

    Maximising pharmaceutical development of novel injectable delivery technologies through sustainable approaches

    Cedric Gysel, Manager, Sustainable Innovation & Circular Economy Solutions at the Office of Sustainability , Johnson & Johnson

  • Designing for the future with sustainable device designs and partial reusability
  • Where does the industry need to collaborate on policy to enable circular supply chains
  • Implementing end of life procedures for device disassembly and correct material disposal
  • Looking to the future, what does the industry need to focus on for further sustainable approaches to device development
  • clock

    17:10

    Chairman’s Closing Remarks and Close of Day Two


    General Manager
    Platinum Pharma Service srls
    Regulatory Professional
    Novo Nordisk
    Manager, Sustainable Innovation & Circular Economy Solutions at the Office of Sustainability
    Johnson & Johnson
    Senior Verification Engineer
    Roche
    Project Leader
    Sanofi
    Director, Senior Expert Nonclinical Safety
    Bayer AG
    Senior Product Specialist
    TÜV SÜD
    Senior Director of QA & RA Compliance for Medical Devices and eHealth
    Bayer AG
    Senior Global Regulatory Professional
    Novo Nordisk
    Assistant Research Manager
    Mitsubishi Gas Chemical Company, Inc
    Senior Director
    AstraZeneca
    Head of Primary Packaging & Process Development
    Boehringer Ingelheim Pharma Gmbh & Co. KG
    Director of Business Development
    ApiJect Systems, Corp.
    Associate Director, Devices
    GSK
    Global Regulatory Specialist | RA Device Combination Products
    Novo Nordisk
    Device Development Lead
    Pfizer
    Associate Scientific Fellow
    Takeda
    Program Manager
    MediPhorum

    Gold Sponsor

    Sponsors

    Exhibitors

    Official Media Partner

    VENUE

    Hilton London Kensington

    179-199 Holland Park Avenue, London, United Kingdom

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    2024 Brochure

    Download

    Past Presentation: Bayer

    Download

    Past Presentation: GSK

    Download

    Past Presentation: BSI

    Download

    Past Presentation: Amgen

    Download

    Past Presentation: BSI

    Download

    2023 Past Attendees

    Download

    Sponsors and Exhibitors


    Althena Medical

    Gold Sponsor
    http://www.althenamedica.it/

    Althena Medical is an Italian company specialized in the development and production of medical devices in the pharmaceutical field (pre-fillable syringes, oral liquid dispensers, droppers, etc.). In our catalogue we currently have COP pre-fillable syringes in several volumes. We also offer filling service and turn-key products.

    We work for small, medium and big brands for which we have designed, created and produced patented products.

    We differ from our competitors because we are flexible, reliable and we develop medical devices on demand very quickly.

    100% Made in Italy!


    Sponsors


    ApiJect™

    Sponsors
    https://info.apiject.com/industry-events

    ApiJect™ is a global medical technology company creating the future of pharmaceutical injections.

    Our mission is to provide products with superior convenience, quality, and safety of prefilled syringes at the manufacturing scale and cost-efficiency of multi-dose formats – regardless of manufacturing volume. 

    Our Platform brings together two globally trusted manufacturing technologies: Blow-Fill-Seal (BFS) aseptic filling and high-precision plastic injection molding. Our supply chain is simple and compact, using widely available raw materials, ensuring reliability and resilience.  

    The promise of our platform can be seen in our first device, a single-dose prefilled injector is designed to enhance commercial markets and global healthcare accessibility, enabling a wider range of healthcare professionals to administer necessary medications and vaccines to patients.



    Mitsubishi Gas Chemical

    Sponsors
    https://www.mgc.co.jp/eng/products/abd/oxycapt.html

    Mitsubishi Gas Chemical is a leading company in the field of oxygen barrier and absorbing technologies. Based on these technologies and experiences, we have successfully developed multilayer plastic vial and syringe having excellent oxygen, ultra violet and water vapor barrier. The products make it possible to replace glass with plastic for injectable drugs.

    Exhibitors


    KORU

    Exhibitors
    https://www.korumedical.com/

    KORU is, first and foremost, a patient-centric organization that will go the extra mile for our customers, providers, and partners who depend on our devices. We are a world-class manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).


    Media Partners


    Pharma network magazine

    Official Media Partner
    https://www.pharmanetwork.digital

    PHARMAnetwork is a company specialized in publishing for the pharmaceutical industry. PHARMAnetwork has developed publications for CMO, CDMO and professionals working in the life sciences. PHARMAnetwork designs specialized studies for pharmaceutical companies, contract service providers and investment firms. PHARMAnetwork magazine covers, every aspect of pharmaceutical value chain, the change and developments in the intersection between pharmaceutical industry and outsourcing industry. We perform interviews and write articles whose thematic strategies, organizations, mergers and acquisitions, regulatory, innovation in the pharmaceutical development and contract manufacturing. https://www.pharmanetwork.digital


    The Medicine Maker

    Official Media Partner
    https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo

    The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo


    Pharma Journalist

    Official Media Partner
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    pharmaphorum

    Official Media Partner
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    On Drug Delivery

    Official Media Partner
    http://www.ondrugdelivery.com/subscribe

    ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”
    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.